We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Pet Pharma Co. Sidesteps Investor Suit Over Dog Drug Delays

Law360 (June 12, 2018, 5:17 PM EDT) -- A veterinary pharmaceutical company likely didn't mislead investors about the timeline for bringing an appetite stimulant for dogs to market, a New York federal judge said Monday in dismissing a proposed securities class action alleging that a delay in the drug's availability caused the company's stock to nosedive.

U.S. District Judge Paul A. Engelmayer said lead plaintiffs Joseph Bessent, John Corbitt and Eric Pearson fell short of showing Aratana Therapeutics Inc. and two of its officers had perpetrated a securities fraud, finding investors hadn’t shown the...
To view the full article, register now.




Case Information

Case Title

In re Aratana Therapeutics Inc. Securities Litigation

Case Number



New York Southern

Nature of Suit



Paul A. Engelmayer

Date Filed

February 6, 2017

Law Firms

Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.